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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) has
typically utilized myeloablative host preparative regimens of
high-dose cyclophosphamide (Cy) combined with other
alkylating agents or total body irradiation (TBI) [1]. Such
myeloablative regimens deplete immune-competent T cells
and thus reduce the host-versus-graft rejection re s p o n s e .
However, the use of myeloablative preparative regimens in
allogeneic BMT has several drawbacks. Myeloid ablation
with subsequent neutropenia contributes to the incidence
and severity of infections post-BMT [2], and is associated
with a wide range of nonhematologic toxicities [3]. In addi-
tion, gastrointestinal damage induced by myeloablative
re g imens contributes to the initiation of graft-versus-host
d i sease (GVHD) [4-6]. Given that data from primate mod-
els have shown that immune-competent T cells can survive
myeloablative regimens and mediate the rejection of allo-
grafts [7], the use of myeloablative regimens for the
p re v e ntion of marrow rejection appears to have a narro w
t h e r a p e utic index. As such, there is a need to develop effec-
tive approaches to prevent graft rejection that may poten-
tially reduce the toxicities associated with allogeneic BMT. 
In this study, we have developed a murine F1-into-
p a rent marrow rejection model using purine analog–based
p reparative regimens to evaluate the engraftment eff e c t s
of such regimens independent of GVHD. Given that
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ABSTRACT
The prevention of graft rejection in the setting of nonmyeloablative transplant approaches might be mediated by
chemotherapy-induced host immunoablation and by the graft-promoting effects of graft-versus-host disease (GVHD).
To evaluate whether host immunoablation alone might allow for alloengraftment, we developed an F1-into-pare n t
murine marrow rejection model using host preparative regimens of lethal total body irradiation (TBI; 950 cGy), sub-
lethal irradiation (600 cGy), or combinations of fludarabine (Flu) and cyclophosphamide (Cy). A preparative re g i m e n
selectivity index (SI) was calculated to determine whether host lymphocytes were pre f e rentially depleted relative to
myeloid cells (SI = number of host myeloid/number host T lymphoid cells remaining after preparative regimen admin-
istration). Saline-treated recipients were assigned an SI value of 1.0. Recipients of lethal TBI had reduced myeloid
cells relative to T cells (SI = 0.6). In contrast, all Flu/Cy regimens pre f e rentially depleted host T cells: recipients of
Flu (100 mg/kg per day)/Cy (50 mg/kg per day) for 10 days (SI = 28.1); recipients of Flu (100 mg/kg per day)/Cy
(100 mg/kg per day) for 10 days (SI = 64.1); and recipients of Flu (100 mg/kg per day)/Cy (50 mg/kg per day) for 19 or
27 days (SI = 74.6). The 10-day regimen of Flu/Cy (50 mg/kg per day) did not severely reduce host T cell numbers,
nor did it prevent F1 marrow rejection (<1% chimerism, n = 14). In contrast, the 10-day regimen of Flu/Cy
( 1 0 0 mg/kg per day) reduced T-cell numbers below that of lethal TBI recipients and prevented F1 marrow re j e c t i o n
(11.4% chimerism, n = 15); donor chimerism was predominant in lymphoid cells and was stable through day 240 post-
B M T. Additionally, the 19- or 27-day regimen of Flu/Cy, which most selectively depleted host T cells, also pre v e n t e d
F1 marrow rejection (6.3% chimerism, n = 15). These results there f o re demonstrate that optimized Flu-containing,
immunoablative preparative regimens can prevent fully MHC-disparate marrow rejection independent of GVHD.
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a l l o re a ctive T-cell responses that induce GVHD also pre-
vent marrow rejection [8], it is difficult to estimate the con-
tribution of the purine analog–containing preparative re g-
imens to the prevention of graft rejection in settings
w h e re the potential for alloreactivity exists. For example,
in the clinical setting of human leukocyte antigen (HLA)-
matched, T c e l l – replete peripheral blood stem cell trans-
plantation using a fludarabine (Flu)-based preparative re g i-
men, a significant incidence of both graft rejection and
GVHD was observed [9]. Another clinical result with a Flu-
based preparative regimen was not associated with a signifi-
cant incidence of graft rejection but was associated with
significant GVHD [10]. Similar to the clinical situation,
animal models of nonmyeloablative allogeneic BMT have
utilized T cell–replete donor grafts in settings where the
potential for alloreactivity exists [11-13]. Because the use of
a l l o reactive T cells for the prevention of graft rejection is
associated with GVHD, we reasoned that advances in the
nonmyeloablative transplant approach might be achieved
t h rough optimization of host T-cell depletion by purine
analog–containing preparative regimens. 
In this report, we demonstrate that Flu and Cy act syn-
e rgistically to deplete murine host T cells, and that tre a t-
ment regimens can be defined that generate severe levels of
host CD4+ and CD8+ T-cell depletion with minimal reduc-
tions in myeloid cells. Furthermore, we have demonstrated
that Flu-based regimens are capable of preventing fully
MHC-mismatched murine marrow rejection without con-
tribution from GVHD effects. Our development of this
murine model demonstrates that purine analog–containing
preparative regimens have great potential for the prevention
of marrow rejection and provides the basis for further stud-
ies evaluating the role of chemotherapy-induced host
immunoablation in allogeneic BMT.
MATERIALS AND METHODS 
M i c e
Adult 8- to 12-week-old C57BL/6 (B6, H-2b) and
B6D2F1 (H-2b / d) mice were bred at the Frederick Cancer
Research Center (Frederick, MD) and housed in a specific
p a t h o g e n – f ree facility at the National Institutes of Health
(Bethesda, MD). 
P re p a r a t i v e Regimens
Flu (kindly provided by the NCI Developmental Thera-
peutics Program) and Cy (kindly provided by the NCI
P h a rmacy; Bristol-Myers Squibb Co., Princeton, NJ) were
a d m i n i s t e red to host B6 mice by intraperitoneal injection
once daily, Monday through Friday, for a total of 10, 19, or
27 days. Flu dose was always 100 mg/kg per day; Cy dose
varied from 25 to 100 mg/kg per day. Other mice were irra-
d iated with either lethal TBI (950 cGy) or sublethal TBI
(600 cGy) using 1 3 7C s γ radiation at a rate of 101 cGy/minute
f rom a Gamma Cell 40 irradiator (Atomic Energy of
Canada, Ottawa, Ontario, Canada). 
Determination of Pr e p a r a t i v e Regimen Effects on
Host Spleen Cell P o p u l a t i o n s
Splenic single cell suspensions were obtained from B6
mice treated with Flu/Cy, lethal or sublethal TBI, or
Hanks’ balanced salt solution (HBSS). Red blood cells were
lysed with ACK buffer (Biofluids, Rockville, MD). The cell
suspensions were counted and analyzed by 2-color flow
c y t o m e t ry; dead cells were gated out by propidium iodide.
Flow cytometry reagents included phycoery t h r in (PE)- and
f l u o rescein isothiocyanate (FITC)-labeled anti-C D 4 ,
anti-CD8, anti-CD19, and anti-Gr-1 (PharMingen, San
Diego,  CA) and anti-Mac-1 (Caltag Laboratories,
Burlingame, CA). The absolute number of cells in a given
population was determined by multiplying the perc e n t a g e
of cells that stained positive for a given lymphoid or
myeloid marker by the total number of spleen cells. The
selectivity index (SI) value for each treatment group was
then determined by taking the total number of myeloid
cells (Mac-1+ and Gr- 1+ populations) and dividing by the
total number of T cells (CD4+ and CD8+ populations). The
SI value obtained for the HBSS-treated group was assigned
a value of 1.0.
M a r row Hematopoietic Progenitor Cell Assay (CFU-
GM, CFU-G, and CFU-M Assa y )
Mice were treated with HBSS, Flu (100 mg/kg per day),
and Cy (100 mg/kg per day) for 10 days or administere d
950 cGy TBI. Bone marrow was extracted from the femurs
24 hours after completion of treatment. Marrow cells were
counted and plated in triplicate at 1 × 1 05 cells per plate in
MethoCult GFM3534 Complete Media that contained
recombinant murine (rm) stem cell factor (SCF), rm inter-
leukin (IL)-3, and rmIL-6 (StemCell Technologies, Vancou-
ver, BC). Each plate was maintained for seven days in cul-
ture at 37°C with humidified air at 5% CO2. After culture,
colonies were counted and recorded as colony-forming units
(CFU); total numbers of CFU/femur and CFU/105 marrow
cells plated were then calculated.
Bone Marrow T r a n s p l a n t
M a rrow was obtained from the femurs and tibias of
B6D2F1 mice and T cell depleted using an anti–T cell anti-
body (clone HO-13-2) [14] and complement (Low-To x - M
Rabbit Complement; Cedarlane Laboratories, Horn b y,
Ontario, Canada). Twenty-four hours after completion of
the preparative regimen, the T cell–depleted marrow cells
w e re injected intravenously into the chemotherapy-tre a t e d
or irradiated mice at a dose of 1 × 107 cells per recipient.
Determination of Chimerism P o s t t r a n s p l a n t
Donor cell chimerism was determined in transplant
recipients by 2-color flow cytometry. Peripheral blood
was obtained from the re t ro-orbital sinus and depleted of
red cells by density centrifugation (Cellsep; 1.077 specific
gravity; Larex, St. Paul, MN). Cells were washed in
HBSS with 1% bovine serum albumin and 0.1% sodium
azide before incubation with purified anti-Fc re c e p t o r
antibody (2.4G2; PharMingen). Cells were then stained
with H2-kb FITC, H2-kd Biotin, or the IgG2 a κ i s o t y p e
c o n t rol, and Strepavidin-PE (all from PharMingen).
Peripheral blood cells from untreated B6 and B6D2F1
mice were used to define positive and negative quad-
rants. Percentage donor chimerism was calculated as fol-
lows: % donor chimerism = (donor cells/[host cells +
donor cells]) × 1 0 0 .
184
Complete Blood Counts, Blood Chemistry, and
H i s t o p a t h o l o gy
Peripheral blood was obtained from Flu/Cy re c i p i e n t s
(100 mg/kg per day of each agent for 10 days) at day 210
p o s t - B M T; complete blood counts and blood chemistry
tests were perf o rmed by the NIH Department of Clinical
Pathology on a Cell-Dyn 3500 automated complete blood
count machine (Abbott Laboratories, Abbott Park, IL). Age-
matched controls were used to determine the norm a l
ranges. Mice that had received the preparative regimens of
950 cGy TBI, 600 cGy TBI, or Flu/Cy were killed on day
240 post-BMT, and tissues were taken for histopathologic
analysis. Brain, spinal cord, sciatic nerve, skeletal nerv e ,
skeletal muscle, skin, heart, lung, liver, kidney, small intes-
tine, colon, cecum, adrenal gland, pancreas, and bone mar-
row were all placed in 10% neutral buff e red formalin and
stained with hematoxylin and eosin.
Statistical Anal y s i s
Data were analyzed by the nonparametric rank sum
analysis of Wilcoxon; P values of <.05 were considered sta-
tistically significant.
RESULTS
Flu and Cy Synergistically Deplete Host T - C e l l
Po p u l a t i o n s
To evaluate whether Flu and Cy were additive or syner-
gistic in the depletion of host lymphocytes, mice were tre a t e d
with Flu (100 mg/kg per day), Cy (25 mg/kg per day), or
both agents for 10 days. As Figures 1A and 1B show, com-
pared to HBSS-treated controls, Flu alone produced a mod-
est reduction in CD4+ and CD8+ T cells (21% decrease in
CD4+ cells; 10% decrease in CD8+ cells). This dose of Flu
has previously been shown to be the highest dose that is not
associated with neurologic toxicity in mice [15]. Administra-
tion of Cy alone also resulted in a modest reduction in
CD4+ and CD8+ T cells (54% decrease in CD4+ cells; 55%
d e c rease in CD8+ cells). However, the combination of Flu
and Cy was highly effective in depleting splenic T cells
(90% reduction in CD4+ cells; 86% reduction in CD8+
cells). If these 2 agents were additive in their effects on host
T-cell depletion, one would expect to see a 75% reduction
in CD4+ cells and a 65% reduction in CD8+ cells. These
results thus demonstrate that Flu and Cy synerg i s t i c a l l y
depleted host CD4+ and CD8+ T cells.
P re p a r a t i v e Regimen–Induced Host Lymphoid and
M y eloid Cell Depletion: Comparison of Flu/Cy
Regimens to TBI
Cohorts of TBI- or Flu/Cy–treated mice were evaluated
for levels of lymphoid and myeloid cells on the day of the
transplant (24 hours after preparative regimen completion).
As Figure 2 shows, mice treated with 950 cGy TBI had
s e v e re spleen cell depletion relative to HBSS-treated mice
( reduction in total spleen cell number from 189 × 1 06 ± 1.1
to 4.7 × 1 06 ± 1.2). The TBI resulted in severe lymphoc y t e
depletion: CD4+ cells went from 9.9 × 1 06 ± 1.6 to 0.6 × 106
± 0.1; CD8 + cells decreased from 12.6 × 106 ± 2.4 to 0.3 ×
106 ± 0.2; and CD19+ cells decreased from 90.3 × 106 ± 4.7
to 0.9 × 1 06 ± 0.3. Host myeloid cells were also severe l y
depleted by the TBI: Mac-1+ cells decreased from 3.6 × 106
± 0.5 to 0.12 × 106 ± 0.02; and Gr-1+ cells decreased from
11.9 × 106 ± 1.5 to 0.25 × 106 ± 0.06. 
Evaluation of mice receiving Flu (100 mg/kg per day) and
Cy (50 mg/kg per day) for 10 days demonstrated that this re g i-
men induced significant lymphoid depletion: splenic CD4+
cells were 0.6 × 1 06 ± 0.2; CD8+ cells were 0.9 × 1 06 ± 0.3; and
C D 1 9+ cells were 0.3 × 1 06 ± 0.1. However, in contrast to the
TBI recipients, myeloid cells were not significantly re d u c e d
Figure 1. Effect of fludarabine (Flu) and cyclophosphamide (Cy) on splenic CD4+ and CD8+ T-cell numbers. B6 mice received 10 days of intraperitoneal treat-
ment with HBSS (n = 5), Flu (100 mg/kg per day, n = 5), Cy (25 mg/kg per day, n = 5), or a combination of Flu and Cy (n = 5). Spleens were harvested and
counted after chemotherapy administration, and splenic single-cell suspensions were evaluated by flow cytometry to identify T-cell subsets. A and B show the absolute
number of CD4+ and CD8+ T cells remaining posttreatment, respectively.
A B
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c o m p a red to the HBSS-treated mice: Mac-1+ cells w e re 6.7 ×
1 06 ± 1.1 (compared to 3.6 × 1 06 ± 0.5) and Gr-1+ cells were
13.9 × 1 06 ± 3.9 (compared to 11.9 × 1 06 ± 1.5). 
Although this regimen of Flu and Cy resulted in the
preferential depletion of lymphoid cells relative to myeloid
cells, the absolute level of host T-cell depletion was not as
s e v e re as in the TBI-treated mice. To evaluate whether
m o re severe host T-cell depletion might be achieved with
dose intensification of Cy, mice were treated with the same
dose of Flu (100 mg/kg per day) and a higher dose of Cy
(100 mg/kg per day). As Figure 2 shows, this re g i m e n
depleted host lymphoid cells to levels even lower than TBI-
t reated mice: CD4+ cells were at 0.04 × 1 06 ± 0.01 (signifi-
cantly lower than TBI; P = .003); CD8+ cells were 0.03 × 1 06
± 0 . 0 1 (significantly lower than TBI; P = .008); and CD19+
cells w e re 0.08 × 1 06 ± 0.04 (significantly lower than
TBI; P = .03). A d d i t i o n a l l y, this regimen resulted in less
myeloid suppression relative to the TBI recipients: Mac-1+
cells were 0.81 × 1 06 ± 0.3 (versus TBI value of 0.12 × 1 06
+ 0.02; P = .04); and Gr-1+ cells were 1.5 × 106 ± 0.6 (versus
TBI value of 0.25 × 106 ± 0.06; P = .04). However, this regi-
men did result in a reduction in myeloid cells relative to the
HBSS control group (reduced Mac-1+ and Gr-1+ cells, both
at the P = .04 level of significance). In addition, this regim e n
was associated with weight loss and a 10% to 20% occurrence
of lethality during drug administration.
Because the 10-day regimen of Flu with the higher dose
of Cy (100 mg/kg per day) was associated with some
myeloid suppression and toxicity, we sought to define alter-
native regimens. We evaluated whether administration of
Flu with the lower dose of Cy (50 mg/kg per day) for pro-
longed periods (19 or 27 days) might result in severe host
T-cell depletion without significant myeloid suppre s s i o n .
C o m p a red to administration of 950 cGy TBI, pro l o n g e d
Flu and Cy administration to mice resulted in reduced levels
of host CD4+ T cells (0.1 × 106 ± 0.04; P = .01), and a similar
level of CD8+ T-cell depletion (0.06 × 106 ± 0.05; P = .77).
Importantly, this Flu/Cy regimen did not reduce the Mac-1+
cells relative to HBSS-treated mice (Mac-1+cells: 4.6 × 1 06
± 0 . 5 , P = .09). However, relative to the HBSS contro l
recipients, this regimen did result in a modest decrease in
host granulocytes (Gr-1+cells; 3.6 × 106 ± 0.7, P = .01).
To quantify the relative ability of a given pre p a r a t i v e
regimen to deplete host T lymphoid versus myeloid lin-
eages, we developed a selectivity index based on the absolute
number of splenic subpopulations remaining posttreatment:
(SI = [Mac +Gr]/[CD4 + CD8]). As Figure 3 shows, 950 cGy
TBI was relatively nonselective (SI value of 0.6), as it severe l y
depleted both myeloid and T lymphoid lineages. In con-
trast, the 10-day regimen of Flu (100 mg/kg per day) and Cy
(50 mg/kg per day) preferentially depleted host T cells (SI
value of 28.1). An increase in either Cy dose or tre a t m e n t
Figure 2. Host spleen cell populations remaining after treatment with either total body irradiation or combinations of fludarabine (Flu) and cyclophosphamide
(Cy). Mice were treated with (1) HBSS, n = 13; (2) 950 cGy TBI, n = 11; (3) Flu (100 mg/kg per day) and Cy (100 mg/kg per day) for 10 days, n = 11;
(4) Flu (100 mg/kg per day) and Cy (50 mg/kg per day) for 10 days, n = 8; or (5) Flu (100 mg/kg per day) and Cy (50 mg/kg per day) for 19 or 27 days,
n = 9. Spleen cells were counted, and cells were examined by flow cytometry to determine the yields of CD4+, CD8+, CD19+, Mac-1+, and Gr-1+ cell subsets post-
treatment. The average ± the standard error of the mean is shown for each treatment group. Results were pooled from 3 experiments, each having a HBSS and a
950 cGy irradiation treatment cohort.
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duration further increased the selectivity index: the 10-day
regimen of Flu and Cy (100 mg/kg per day) had an SI value
of 64.2, and the regimen of Flu and Cy (50 mg/kg per day)
for 19 or 27 days had an SI value of 74.6.
E f f ect of Flu/Cy Regimen Versus TBI on Marrow
Hematopoietic Progenitor Cells
In addition, we evaluated marrow hematopoietic pro-
genitor cell activity after the 10-day regimen of Flu/Cy
(100 mg/kg per day of each agent; n = 3) or after 950 cGy
TBI (n = 3). After treatment with Flu/Cy, the 2-femur mar-
row cell yield was 14.2 × 1 06 ± 0.3, which was much higher
than that observed for recipients of the 950 cGy TBI (0.3 ×
1 06 ± 0.1). Furt h e rm o re, combined evaluation of the mar-
row yield and the marrow CFU assay (data not shown)
demonstrated that the Flu/Cy recipients had significantly
m o re CFU per femur than the 950 cGy TBI–treated mice
(126 versus 2; P = .01); the value obtained for HBSS-tre a t e d
c o n t rol recipients was 240 CFU per femur. As such, the
9 5 0 cGy TBI regimen resulted in a far greater reduction in
host hematopoietic marrow progenitor cell function than
the Flu/Cy re g i m e n .
Transplantation of F1 Marrow Into P a re n t a l
Recipients of Flu and Cy Results in Stable Mix e d
C h i m e r i s m
Having shown that 3 diff e rent combinations of Flu and
Cy resulted in significant host T-cell depletion, we next eval-
uated whether F1 marrow graft rejection might be pre v e n t e d
in such recipients. Parental B6 hosts received Flu (100 mg/kg
per day) and Cy (50 or 100 mg/kg per day) for a 10-day
period prior to F1 marrow transplantation. Figure 4 shows
the peripheral blood chimerism results by flow cytometry at
day 30 posttransplant in these recipients. As expected, graft
rejection was prevented in recipients of the high-dose total
body irradiation (950 cGy TBI, n = 13; average F1 chimerism
of 95.1% ± 0.5). In contrast, recipients of the 10-day tre a t-
ment of Flu and low-dose Cy (50 mg/kg per day) eff e c t i v e l y
rejected the F1 marrow graft (Flu/Cy 100/50, n = 14; average
F1 chimerism of <1%). At the time of transplant, these Flu/Cy
recipients had levels of residual CD8+ T cells that were higher
than the recipients of the lethal TBI. In contrast, recipients of
Flu and a higher dose of Cy (100 mg/kg per day) had a level
of host CD8+ T-cell depletion that was comparable to the
lethal TBI group, and such recipients had evidence of F1
m a rrow engraftment (Flu/Cy 100/100, n = 15; average F1
chimerism at day 30 post-BMT of 11.4% ± 4.2). Chimerism
in this treatment group appeared to be stable through day 240
posttransplant (see Table 1). 
P ro l o n g ed Treatment of P a r ental Mice With Flu 
(100 mg/kg per day) and Cy (50 mg/kg per da y )
P r events F1 Marrow Rejection
Although graft rejection was prevented by treatment of
parental mice with 10 days of Flu/Cy (100 mg/kg per day),
this regimen was associated with some myeloid suppression
and toxicity. As such, we evaluated other combinations of
Flu and Cy and determined that prolonged administration
(19 or  27 days) of Flu (100 mg/kg per day) and Cy
( 5 0 mg/kg per day) was well tolerated and associated with
severe host T-cell depletion and minimal myeloid suppres-
sion (Figure 2). As Figure 5 shows, there was evidence of
donor engraftment in re c i p ients of this prolonged regimen
of Flu and Cy (average F1 chimerism at day 70 of 6.3% ± 0.8,
n = 12; positive chimerism relative to the 600 cGy irradia-
tion rejection control group, P = .04). 
Donor Chimerism in Flu/Cy–Treated Recipients Is
P re d o m i n a n t l y of Lymphoid Lineage
To evaluate which cell populations contributed to the
mixed chimerism observed in the F1 recipients of the
Flu/Cy regimens, spleens from transplant recipients were
h a rvested on day 240 posttransplant and evaluated by flo w
cytometry for both the donor marker (H-2d) and lymphoid
or myeloid markers. As Table 1 shows, 950 cGy TBI–treated
mice displayed a high level of donor chimerism in both
Figure 3. Preparative regimen depletion of host myeloid versus T-lymphoid populations: selectivity index (SI). Based on data shown in Figure 2, a selectivity
index was calculated to relate depletion of host myeloid versus lymphoid populations quantitatively: SI value = Mac-1+ and Gr-1+ cells remaining posttreatment
divided by the number of CD4+ and CD8+ cells remaining. The value obtained for the HBSS control group was assigned an SI value of 1.0. 
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myeloid and lymphoid cells. In contrast, 3 of 4 recipients of
the Flu/Cy preparative regimen (100 mg/kg per day of each
agent for 10 days) had much higher levels of donor
chimerism in lymphoid cells than in myeloid cells.
We observed that transplant recipients of this Flu/Cy
regimen (100 mg/kg per day of each agent for 10 days) devel-
oped significant weight loss posttransplant (appro x i m a t e l y
30% reduction in body weight by day 240 posttransplant). To
evaluate potential causes of this clinical state, complete blood
count, blood chemistry, and histopathology were obtained on
Flu/Cy recipients between day 210 and 240 posttransplant.
Such transplant recipients had moderate ketonuria by dipstick
evaluation using N-Multistix SG Urine Chemistry Reagent
Strips (Bayer Diagnostics, Ta rrytown, NY). However, other
metabolic tests, including serum electrolytes, blood ure a
n i t ro g e n / c reatinine, liver transaminases, bilirubin, and cre a-
tine phosphokinase were all within normal limits of the
assays. Additionally, complete blood count results showed
that chimeric mice had normal hemoglobin levels, white
blood cell counts, white blood cell diff e rentials, and platelet
counts. Furt h e rm o re, complete histopathology analysis of all
o rgans failed to reveal any specific lesions of GVHD, infec-
tion, or end organ damage. As such, a thorough evaluation
failed to reveal any specific cause for the observed weight loss.
DISCUSSION
In this re p o rt, we have demonstrated that purine analog–
containing preparative regimens can prevent fully MHC-
disparate murine marrow graft rejection independent of
GVHD effects. We have shown that Flu and Cy act syner-
gistically to deplete host T cells, and that regimens can be
defined to maximize immune ablation with minimal myeloid
s u p p ression. In addition to demonstrating the potency of
purine analog–based regimens in the prevention of marrow
rejection, these studies provide a framework for furt h e r
F i g u r e 4. Determination of peripheral blood chimerism in F1-into-parent marrow transplantation after fludarabine (Flu) and cyclophosphamide (Cy) preparative
r e g imens of 10-day duration. Host B6 mice were treated with (1) 950 cGy total body irradiation, n = 13; (2) Flu (100 mg/kg per day) and Cy (100 mg/kg per day)
for 10 days (Flu/Cy 100/100), n = 15; or (3) Flu (100 mg/kg per day) and Cy (50 mg/kg per day) for 10 days (Flu/Cy 100/50), n = 14. Twenty-four hours after
completion of the preparative regimen, mice received an intravenous injection of T cell–depleted marrow from B6D2F1 mice (1 × 1 07 cells/recipient). At 30 days post-
transplant, peripheral blood was collected and evaluated for chimerism by 2-color flow cytometry. Results were pooled from 3 separate experiments.
Table 1. Immunoablative Fludarabine (Flu) and Cyclophosphamide (Cy) Preparative Regimens: Lymphoid Versus Myeloid Cell Donor Chimerism 
Percentage Donor Chimerism in Spleen Cell Populations
(Day 240 Post–Bone Marrow Transplant) †
Total Spleen Lymphoid Cells Myeloid Cells
Treatment Group* Cell Number ( ×10 6) Total Cells CD4 + CD8 + CD19 + Gran + Mac-1 +
950 cGy, Subject #1 109 98.3 90.6 74.3 99.0 95.1 78.7
950 cGy, Subject #2 118 98.6 93.8 85.2 99.8 98.9 81.2
600 cGy, Subject #1 104 <1 <1 <1 <1 <1 <1
600 cGy, Subject #2 87 <1 <1 <1 <1 <1 <1
600 cGy, Subject #3 82 <1 <1 <1 <1 <1 <1
Flu/Cy, Subject #1 41 67.8 46.7 43.9 69.0 15.4 22.1
Flu/Cy, Subject #2 42 47.7 19.6 28.5 50.9 9.5 17.5
Flu/Cy, Subject #3 41 21.0 9.0 13.7 21.7 3.9 4.6
Flu/Cy, Subject #4 51 3.1 4.5 4.0 3.3 3.8 3.5
*Treatment groups consisted of B6 host mice that received 950 cGy lethal total body irradiation (TBI), 600 cGy sublethal TBI, or a 10-day preparative regimen of
Flu and Cy (100 mg/kg per day of both agents).
†Spleens were harvested on day 240 after transplantation of T cell–depleted marrow from B6D2F1 mice and evaluated by flow cytometry using the donor-
restricted marker H-2d and the cell lineage–specific markers, as indicated.
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investigations to better understand and optimize i m m u n o-
ablative approaches to allogeneic BMT. 
Our studies demonstrate that in transplant settings not
involving GVHD effects, immunoablative preparative regi-
mens must induce severe depletion of host T cells for the
p revention of marrow rejection. In part i c u l a r, our re s u l t s
indicate that a reduction in host CD4+ and, in part i c u l a r,
C D 8+ T cells to levels comparable to that achieved with
lethal doses of TBI may be re q u i red for the prevention of
fully MHC-disparate marrow graft rejection. Our re s u l t s
indicate that the realization of such severe levels of host
T-cell depletion via purine analog–based chemotherapy
might be accomplished through either prolonging the
period of chemotherapy treatment or intensifying the Cy
dosing. Application of these general principles may be rele-
vant to the development of clinical preparative regimens for
the abrogation of rejection without GVHD, such as in the
setting of T cell–depleted allogeneic BMT.
Our observation that Flu and Cy act synergistically to
deplete host T cells provides the basis for further studies to
optimize immunoablative preparative regimens. This syn-
ergy may be due to the ability of Flu to inhibit DNA synthe-
sis, with subsequent enhanced immune cell susceptibility to
DNA-damaging agents such as Cy [16]. Our results form
the basis for evaluation of other purine analogs, such as
a r a-G [17], or other agents in combination with purine
analogs, such as the topoisomerase II inhibitors [18,19]. 
In addition, our results reveal information about the
n a t u re of engraftment that occurs with immunoablative
regimens in the absence of GVHD. Our experiments indi-
cate that engraftment in this setting is characterized by sta-
ble mixed chimerism, typically with low-level donor ele-
ments. In addition, we found that chimerism was typically
“split,” with lymphoid cells constituting the major compo-
nent of the donor chimerism. This result likely relates to
the preparative re g i m e n ’s selectivity in depleting host
lymphoid elements, with relative sparing of host myeloid
and marrow hematopoietic progenitor elements. This
o b s e rv ation is consistent with the concept that full donor
chimerism may re q u i re the generation of both lymphoid
and myeloid “space” [20,21]. As such, in the absence of an
ongoing graft-versus-host reaction, strategies that generate
host marrow space may be re q u i red to achieve high levels
of donor chimerism after immunoablative preparative re g i-
mens. It should be noted that formal evaluation of lym-
phoid and myeloid space issues would re q u i re experiments
in syngeneic models using the transplantation of congenic
cell populations. Altern a t i v e l y, it is possible that the
o b s e rved pre f e rential donor lymphoid chimerism re s u l t e d
f rom a host-versus-graft immune response that pre f e re n-
tially rejected donor myeloid populations relative to lym-
phoid cells. 
In summary, we have demonstrated that purine analog–
based immunoablative preparative regimens can pre v e n t
fully MHC-disparate murine marrow graft rejection without
contribution from GVHD effects. The further development
of murine models of immunoablative chemotherapy for the
prevention of marrow graft rejection may identify new allo-
geneic transplant preparative regimen strategies. Clinical
translation of such approaches may contribute to an ability
to achieve genetically disparate marrow engraftment with
reduced reliance on GVHD effects.
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